Qiang Lu1,2, Liang Shang3, Wo Tu Tian4, Li Cao4, Xue Zhang1,2,3, Qing Liu1,2. 1. Department of Neurology, Peking Union Medical College Hospital (PUMCH), CAMS & PUMC, Beijing 100730, China. 2. Neuroscience Center, Chinese Academy of Medical Sciences, Beijing 100730, China. 3. McKusick-Zhang Center for Genetic Medicine, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing 100730, China. 4. Department of Neurology and Institute of Neurology, Rui Jin Hospital & Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Abstract
BACKGROUND: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is caused by pathogenic variants in the SACS gene and is characterized by ataxia, peripheral neuropathy, pyramidal impairment and episodic conditions such as epilepsy. Paroxysmal kinesigenic dyskinesia (PKD) had not been previously described in ARSACS. METHODS: We analyzed clinical manifestations and performed whole-exome sequencing (WES) in two independent patients with ARSACS and PKD. Both patients' parents were unaffected. Genetic data were filtered for potential pathogenic variants, searching for de novo mutations suggestive of a dominant disease model or homozygous and compound heterozygous variants of a recessive model. Potential mutations that existed in both patients were generated and subjected to Sanger sequencing. The WES results of 163 PKD patients without additional symptoms from previous experiments were also reviewed. RESULTS: Novel compound heterozygous mutations in the SACS gene were identified in Patient 1 (p.P3007S and p.H3392fs), and a novel homozygous truncating mutation (p.W1376X) was identified in Patient 2. In both patients, each mutant allele was inherited from one of his or her unaffected parents. All 3 mutations were absent in 196 ethnic-matched control chromosomes or in data from the 1000 Genomes Project. No pathogenic variants associated with paroxysmal diseases, especially PKD and episodic ataxia, were identified. In PKD patients without additional symptoms, no homozygous or compound heterozygous variants in the SACS gene were detected. CONCLUSIONS: This study expands the clinical phenotype of ARSACS and suggests the inclusion of SACS screening in patients with PKD plus ARSACS. 2020 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is caused by pathogenic variants in the SACS gene and is characterized by ataxia, peripheral neuropathy, pyramidal impairment and episodic conditions such as epilepsy. Paroxysmal kinesigenic dyskinesia (PKD) had not been previously described in ARSACS. METHODS: We analyzed clinical manifestations and performed whole-exome sequencing (WES) in two independent patients with ARSACS and PKD. Both patients' parents were unaffected. Genetic data were filtered for potential pathogenic variants, searching for de novo mutations suggestive of a dominant disease model or homozygous and compound heterozygous variants of a recessive model. Potential mutations that existed in both patients were generated and subjected to Sanger sequencing. The WES results of 163 PKD patients without additional symptoms from previous experiments were also reviewed. RESULTS: Novel compound heterozygous mutations in the SACS gene were identified in Patient 1 (p.P3007S and p.H3392fs), and a novel homozygous truncating mutation (p.W1376X) was identified in Patient 2. In both patients, each mutant allele was inherited from one of his or her unaffected parents. All 3 mutations were absent in 196 ethnic-matched control chromosomes or in data from the 1000 Genomes Project. No pathogenic variants associated with paroxysmal diseases, especially PKD and episodic ataxia, were identified. In PKD patients without additional symptoms, no homozygous or compound heterozygous variants in the SACS gene were detected. CONCLUSIONS: This study expands the clinical phenotype of ARSACS and suggests the inclusion of SACS screening in patients with PKD plus ARSACS. 2020 Annals of Translational Medicine. All rights reserved.
Authors: Martine Girard; Roxanne Larivière; David A Parfitt; Emily C Deane; Rebecca Gaudet; Nadya Nossova; Francois Blondeau; George Prenosil; Esmeralda G M Vermeulen; Michael R Duchen; Andrea Richter; Eric A Shoubridge; Kalle Gehring; R Anne McKinney; Bernard Brais; J Paul Chapple; Peter S McPherson Journal: Proc Natl Acad Sci U S A Date: 2012-01-17 Impact factor: 11.205
Authors: J Baets; T Deconinck; K Smets; D Goossens; P Van den Bergh; K Dahan; E Schmedding; P Santens; V Milic Rasic; P Van Damme; W Robberecht; L De Meirleir; B Michielsens; J Del-Favero; A Jordanova; P De Jonghe Journal: Neurology Date: 2010-09-28 Impact factor: 9.910
Authors: Roxanne Larivière; Rébecca Gaudet; Benoit J Gentil; Martine Girard; Talita Cristiane Conte; Sandra Minotti; Kim Leclerc-Desaulniers; Kalle Gehring; R Anne McKinney; Eric A Shoubridge; Peter S McPherson; Heather D Durham; Bernard Brais Journal: Hum Mol Genet Date: 2014-09-26 Impact factor: 6.150
Authors: E Gregianin; G Vazza; E Scaramel; F Boaretto; A Vettori; E Leonardi; S C E Tosatto; R Manara; E Pegoraro; M L Mostacciuolo Journal: Eur J Neurol Date: 2013-06-25 Impact factor: 6.089
Authors: Fábio A Nascimento; Laura Canafoglia; Danah Aljaafari; Mikko Muona; Anna-Elina Lehesjoki; Samuel F Berkovic; Silvana Franceschetti; Danielle M Andrade Journal: Neurol Genet Date: 2016-06-23
Authors: Charalampos Tzoulis; Stefan Johansson; Bjørn Ivar Haukanes; Helge Boman; Per Morten Knappskog; Laurence A Bindoff Journal: PLoS One Date: 2013-06-13 Impact factor: 3.240
Authors: Luciana Musante; Paola Costa; Caterina Zanus; Flavio Faletra; Flora M Murru; Anna M Bianco; Martina La Bianca; Giulia Ragusa; Emmanouil Athanasakis; Adamo P d'Adamo; Marco Carrozzi; Paolo Gasparini Journal: Genes (Basel) Date: 2022-03-12 Impact factor: 4.096